| scholarly article | Q13442814 |
| P50 | author | Gerd Mikus | Q37382592 |
| P2093 | author name string | M Eichelbaum | |
| B Vogelgesang | |||
| P2860 | cites work | Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data | Q30558717 |
| Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis | Q34448937 | ||
| Systemic availability of oral verapamil and effect on PR interval in man | Q34449063 | ||
| Influence of meso-caval shunt surgery on verapamil kinetics, bioavailability and response | Q43242625 | ||
| Relationship of antiarrhythmic to inotropic activity and antiarrhythmic qualities of the optical isomers of verapamil | Q46842897 | ||
| Nonlinear least-squares regression programs for microcomputers | Q52231910 | ||
| Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labelled verapamil. | Q52435676 | ||
| Effects on atrioventricular conduction and blood flow of enantiomers of verapamil and of tetrodotoxin injected into the posterior and the anterior septal artery of the atrioventricular node preparation of the dog | Q52701844 | ||
| Verapamil kinetics in normal subjects and patients with coronary artery spasm | Q52733119 | ||
| Determination of verapamil in human plasma by mass fragmentography using stable isotope-labelled verapamil as internal standard | Q52821925 | ||
| Physiological disposition of verapamil in man | Q57072038 | ||
| Effects of verapamil on P-R-intervals in relation to verapamil plasma levels following single i.v. and oral administration and during chronic treatment | Q57072042 | ||
| The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses | Q70283797 | ||
| Clinical pharmacokinetics of verapamil in patients with atrial fibrillation | Q70478662 | ||
| Comparison of intravenous and oral verapamil dosing | Q70509532 | ||
| Superiority of stable isotope techniques in the assessment of the bioavailability of drugs undergoing extensive first pass elimination. Studies of the relative bioavailability of verapamil tablets | Q70681056 | ||
| Verapamil disposition kinetics in chronic atrial fibrillation | Q70791160 | ||
| Direct determination of hepatic extraction of verapamil in cardiac patients | Q70791163 | ||
| Effects of verapamil and its optical isomers on repetitive slow responses induced by electrical depolarization in canine ventricular myocardium | Q71189953 | ||
| Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships | Q71472633 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 453-458 | |
| P577 | publication date | 1984-04-01 | |
| P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
| P1476 | title | Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration | |
| P478 | volume | 17 |
| Q40633547 | (R)- and (S)-[11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation. |
| Q42585832 | A combined accelerator mass spectrometry-positron emission tomography human microdose study with 14C- and 11C-labelled verapamil. |
| Q41180399 | A comparative review of the adverse effects of calcium antagonists |
| Q54191138 | A phase I trial of intrahepatic verapamil and doxorubicin. Regional therapy to overcome multidrug resistance. |
| Q40359652 | A physiologically based pharmacokinetic model to predict the pharmacokinetics of highly protein-bound drugs and the impact of errors in plasma protein binding |
| Q47285157 | A semi-automated method for the integrated evaluation of half-life and metabolic soft spots of discovery compounds |
| Q73073722 | Achiral and chiral high-performance liquid chromatography of verapamil and its metabolites in serum samples |
| Q34347537 | Age and gender related changes in stereoselective pharmacokinetics and pharmacodynamics of verapamil and norverapamil |
| Q36947632 | Age dependency of cerebral P-gp function measured with (R)-[11C]verapamil and PET. |
| Q68631795 | Analysis of drugs and other toxic substances in biological samples for pharmacokinetic studies |
| Q36517093 | Applications of minimal physiologically-based pharmacokinetic models |
| Q41565334 | Bioequivalence of chiral drugs. Stereospecific versus non-stereospecific methods |
| Q56832288 | Cardiovascular effects of (R)- and (S)-verapamil and racemic verapamil in humans: a placebo-controlled study |
| Q36705746 | Chiral aspects of drug action at ion channels: A commentary on the stereoselectivity of drug actions at voltage-gated ion channels with particular reference to verapamil actions at the Ca2+ channel |
| Q36820837 | Chiral stereoisomeric molecules in the treatment of arthritis |
| Q38679209 | Chirality: pharmacokinetics and pharmacodynamics in 3 dimensions |
| Q36115910 | Clinical pharmacokinetics of calcium antagonists. An update |
| Q39754378 | Clinical pharmacokinetics of verapamil, nifedipine and diltiazem |
| Q68019659 | Column-switching high-performance liquid chromatography for on-line simultaneous determination and resolution of enantiomers of verapamil and its metabolites |
| Q71267288 | Determination of R(+)- and S(-)-lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humans |
| Q58860170 | Determination of salbutamol enantiomers by high-performance capillary electrophoresis and its application to dissolution assays |
| Q42807085 | Development of 2D chiral chromatography with accelerator mass spectrometry for quantification of (14)C-labeled R- and S-verapamil in plasma. |
| Q36582463 | Drug disposition in three dimensions: an update on stereoselectivity in pharmacokinetics |
| Q46955216 | Effect of naringin pretreatment on bioavailability of verapamil in rabbits |
| Q34597408 | Effect of pioglitazone on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rats |
| Q42138751 | Effects of calcium channel blockers on the development of early rat postimplantation embryos in culture |
| Q43246010 | Effects of lovastatin on the pharmacokinetics of verapamil and its active metabolite, norverapamil in rats: possible role of P-glycoprotein inhibition by lovastatin |
| Q43158040 | Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats |
| Q40087720 | Enantioselective disposition of ofloxacin in humans |
| Q56832394 | Enantioselective gallopamil protein binding |
| Q47678802 | Enantioselective tissue distribution of the basic drugs disopyramide, flecainide and verapamil in rats: role of plasma protein and tissue phosphatidylserine binding |
| Q46617166 | Enhanced bioavailability of verapamil after oral administration with hesperidin in rats |
| Q43204832 | Evaluation of potential pharmacodynamic and pharmacokinetic interactions between verapamil and propranolol in normal subjects |
| Q54152616 | Fully automated high yield synthesis of (R)- and (S)-[11C]verapamil for measuring P-glycoprotein function with positron emission tomography |
| Q35802166 | Gut wall metabolism of verapamil in older people: effects of rifampicin-mediated enzyme induction |
| Q46706108 | Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles |
| Q34725737 | Impact of stereoselectivity on the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs |
| Q39834900 | Importance of drug enantiomers in clinical pharmacology |
| Q37544345 | Molecular asymmetry and its pharmacological consequences |
| Q38023576 | New concepts affecting the use of antiarrhythmic agents |
| Q52262360 | New mathematical implementation of generalized pharmacodynamic models: method and clinical evaluation. |
| Q37742565 | Nonlinear pharmacokinetics: clinical Implications |
| Q36953090 | PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo |
| Q34396966 | Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate |
| Q35976246 | Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent D-verapamil |
| Q39662361 | Pharmacokinetic interactions of cimetidine 1987. |
| Q42005077 | Pharmacokinetics and pharmacodynamics of verapamil following sublingual and oral administration to healthy volunteers |
| Q28282551 | Pharmacokinetics of (+)-rolipram and (-)-rolipram in healthy volunteers |
| Q64885687 | Pharmacokinetics of S(+)- and R(-)-ibuprofen in volunteers and first clinical experience of S(+)-ibuprofen in rheumatoid arthritis. |
| Q39513598 | Pharmacokinetics of calcium antagonists under development |
| Q43916480 | Pharmacokinetics of controlled-release verapamil in healthy volunteers and patients with hypertension or angina. |
| Q41095274 | Pharmacokinetics of the enantiomers of verapamil in the dog. |
| Q46511734 | Pharmacokinetics of verapamil and its major metabolite, norverapamil from oral administration of verapamil in rabbits with hepatic failure induced by carbon tetrachloride |
| Q69720626 | Pharmacokinetics of verapamil in patients with hypertension |
| Q51250114 | Prediction of hepatic plasma clearance in vivo from gel-entrapped rat and human hepatocytes. |
| Q77331770 | Properties of the racemic species of verapamil hydrochloride and gallopamil hydrochloride |
| Q48420233 | Quantitative determination of disopyramide, verapamil and flecainide enantiomers in rat plasma and tissues by high-performance liquid chromatography. |
| Q43554159 | Race but not age affects erythromycin breath test results in older hypertensive men. |
| Q36003980 | Relationship between the stereoselective negative inotropic effects of verapamil enantiomers and their binding to putative calcium channels in human heart |
| Q43222574 | Serum binding of nifedipine and verapamil in patients with ischaemic heart disease on monotherapy |
| Q72598322 | Simple and reliable radioreceptor assay for beta-adrenoceptor antagonists and active metabolites in native human plasma |
| Q40529605 | Stereochemistry in pharmacotherapy: when mirror images are not identical |
| Q39746510 | Stereochemistry: a source of problems in medicinal chemistry |
| Q34447697 | Stereoselective disposition of mexiletine in man |
| Q42126042 | Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique |
| Q73204587 | Stereoselective metabolism of famprofazone in humans: N-dealkylation and beta- and p-hydroxylation |
| Q45720989 | Stereoselective plasma protein binding of ibuprofen enantiomers |
| Q40832872 | Stereoselectivity in S- and N-oxygenation by the mammalian flavin-containing and cytochrome P-450 monooxygenases |
| Q37946823 | Stereoselectivity in clinical pharmacokinetics and drug development |
| Q37229338 | Stereoselectivity in pharmacokinetics: a general theory |
| Q39529348 | Stereoselectivity: an issue of significant importance in clinical pharmacology |
| Q40458699 | The Genetic Basis of Resistance to Cancer Chemotherapy |
| Q45162718 | The effect of quercetin on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rabbits |
| Q44862793 | The influence of cimetidine on the pharmacokinetics of the enantiomers of verapamil in the dog during multiple oral dosing |
| Q34191085 | The mechanism of action of the optical enantiomers of verapamil against ischaemia-induced arrhythmias in the conscious rat. |
| Q68859240 | The pharmacokinetics of d-sotalol and d,l-sotalol in healthy volunteers |
| Q53763140 | The stereoselectivity of the 'single drug binding site' of human alpha 1-acid glycoprotein (orosomucoid). |
| Q35170048 | Therapeutic drug monitoring of antiarrhythmic drugs |
| Q37909320 | Therapeutic drug monitoring of antiarrhythmic drugs. Rationale and current status |
| Q30858015 | Thin-layer chromatography separation of enantiomers of verapamil using macrocyclic antibiotic as a chiral selector |
| Q51586621 | Verapamil stereoisomerism: Enantiomeric ratios in plasma dependent on peak concentrations, oral input rate, or both* |
| Q38679740 | Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension |
Search more.